Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

On Thursday, Reuters reported weak U.S. prescription data is contributing to investor concerns that Novo Nordisk is no longer ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

A federal judge refused to allow drug compounders to keep making copycats of Novo Nordisk A/S’s weight loss drug while a ...

Pharmaceutical company Novo Nordisk will expand its production site in Montes Claros, Brazil, creating 600 jobs.

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and ...

The “Symposium on Artificial Intelligence and Pharmacology – Present and Future” will be held on June 3rd, 2025, in Copenhagen, bringing together 140 persons across disciplines to foster collaboration ...

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Co. (PG), Novo Nordisk A/S (NVO) and PepsiCo, Inc. (PEP), as well as two micro-cap stocks ...

No­vo Nordisk is pour­ing 6.4 bil­lion Brazil­ian reais ($1.05 bil­lion) in­to a fac­to­ry in Brazil, to ramp up pro­duc­tion of its block­buster GLP-1 drugs af­ter … ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to increase production of its flagship glucagon-like peptide 1 receptor ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...